{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:21:56Z","timestamp":1793650916320,"version":"4.5.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Olle Engkvist Foundation"},{"DOI":"10.13039\/501100021592","name":"Ekhaga Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100021592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Norrsken Mind"},{"DOI":"10.13039\/100008460","name":"National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","award":["K23AT010879"],"award-info":[{"award-number":["K23AT010879"]}],"id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001395","name":"Wisconsin Alumni Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020157","name":"Wisconsin Center for Education Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020157","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012787","name":"Office of the Vice Chancellor for Research and Graduate Education, University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012787","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Alabama at Birmingham School of Public Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-37609-5","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:14:29Z","timestamp":1769634869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence, types, and demographic characteristics associated with major life changes following psychedelic use"],"prefix":"10.1038","volume":"16","author":[{"given":"Nicholas A.","family":"Carlisle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"MacCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc N.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Shallcross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Hendricks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"15","key":"37609_CR1","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris, R. et al. Trial of psilocybin versus Escitalopram for depression. N Engl. J. Med. 384 (15), 1402\u20131411 (2021).","journal-title":"N Engl. J. Med."},{"issue":"15","key":"37609_CR2","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jama.2025.13481","volume":"334","author":"R Robison","year":"2025","unstructured":"Robison, R. et al. Single treatment with MM120 (Lysergide) in generalized anxiety disorder: A randomized clinical trial. JAMA 334 (15), 1358\u20131372 (2025).","journal-title":"JAMA"},{"issue":"12","key":"37609_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J. Psychopharmacol. 30 (12), 1181\u20131197 (2016).","journal-title":"J. Psychopharmacol."},{"issue":"12","key":"37609_CR4","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J. Psychopharmacol. 30 (12), 1165\u20131180 (2016).","journal-title":"J. Psychopharmacol."},{"issue":"10","key":"37609_CR5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz, M. P. et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry. 79 (10), 953 (2022).","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"37609_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson, M. W., Garcia-Romeu, A. & Griffiths, R. R. Long-term follow-up of psilocybin-facilitated smoking cessation. Am. J. Drug Alcohol Abuse. 43 (1), 55\u201360 (2017).","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"37609_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41386-023-01656-7","volume":"49","author":"JM Mitchell","year":"2024","unstructured":"Mitchell, J. M. & Anderson, B. T. Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacol 49, 96\u2013103 (2024).","journal-title":"Neuropsychopharmacol"},{"key":"37609_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/jclp.20000","volume":"60","author":"WR Miller","year":"2004","unstructured":"Miller, W. R. The phenomenom of quantum change. J. Clin. Psychol. 60, 453\u2013460 (2004).","journal-title":"J. Clin. Psychol."},{"issue":"4","key":"37609_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie, T., Seifert, J., Schneider, U. & Emrich, H. M. The Pharmacology of psilocybin. Addict. Biol. 7 (4), 357\u2013364 (2002).","journal-title":"Addict. Biol."},{"issue":"3","key":"37609_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths, R. R., Richards, W. A., McCann, U. & Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacol. (Berl). 187 (3), 268\u2013283 (2006).","journal-title":"Psychopharmacol. (Berl)"},{"issue":"4","key":"37609_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths, R. R. et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacolgy (Berl). 218 (4), 649\u2013665 (2011).","journal-title":"Psychopharmacolgy (Berl)"},{"key":"37609_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/7854_2016_459","volume":"36","author":"KH Preller","year":"2018","unstructured":"Preller, K. H., Vollenweider, F. X. & Phenomenology Structure, and dynamic of psychedelic States. Curr. Top. Behav. Neurosci. 36, 221\u2013256 (2018).","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"4","key":"37609_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/09540261.2018.1474185","volume":"30","author":"PS Hendricks","year":"2018","unstructured":"Hendricks, P. S. Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. Int. Rev. Psychiatry. 30 (4), 331\u2013342 (2018).","journal-title":"Int. Rev. Psychiatry"},{"issue":"4","key":"37609_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1124\/pharmrev.121.000514","volume":"74","author":"HM Dourron","year":"2022","unstructured":"Dourron, H. M., Strauss, C. & Hendricks, P. S. Self-Entropic broadening theory: toward a new Understanding of self and behavior change informed by psychedelics and psychosis. Pharmacol. Rev. 74 (4), 982\u20131027 (2022).","journal-title":"Pharmacol. Rev."},{"key":"37609_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"F Vollenweider","year":"2010","unstructured":"Vollenweider, F. & Kometer, M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat. Rev. Neurosci. 11, 642\u2013651 (2010).","journal-title":"Nat. Rev. Neurosci."},{"issue":"9","key":"37609_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris, R. L. & Nutt, D. J. Serotonin and brain function: a Tale of two receptors. J. Psychopharmacol. 31 (9), 1091\u20131120 (2017).","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"37609_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0269881117731279","volume":"32","author":"RR Griffiths","year":"2018","unstructured":"Griffiths, R. R. et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J. Psychopharmacol. 32 (1), 49\u201369 (2018).","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"37609_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/0269881120967878","volume":"35","author":"AK Davis","year":"2021","unstructured":"Davis, A. K. et al. Development of the psychological insight questionnaire among a sample of Pepole who have consumed psilocybin or LSD. J. Psychopharmacol. 35 (4), 437\u2013446 (2021).","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"37609_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/02698811211066709","volume":"36","author":"JM Peill","year":"2022","unstructured":"Peill, J. M. et al. Validation of the psychological insight scale: A new scale to assess psychological insight following a psychedelic experience. J. Psychopharmacol. 36 (1), 31\u201345 (2022).","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"37609_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/psychoactives2040017","volume":"2","author":"D Perkins","year":"2023","unstructured":"Perkins, D. et al. Insights, life changes and lifestyle changes reported by individuals consuming Ayahuasca in naturalistic settings: Nature, frequency and associations with mental health and wellbeing. Psychoactives 2 (4), 256\u2013286 (2023).","journal-title":"Psychoactives"},{"issue":"1","key":"37609_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s44271-024-00120-6","volume":"2","author":"HT McGovern","year":"2024","unstructured":"McGovern, H. T. et al. An integrated theory of false insights and beliefs under psychedelics. Commun. Psychol. 2 (1), 69 (2024).","journal-title":"Commun. Psychol."},{"issue":"2","key":"37609_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1556\/2054.2021.00155","volume":"5","author":"PG Johnstad","year":"2021","unstructured":"Johnstad, P. G. Day trip to hell: A mixed methods study of challenging psychedelic experiences. J. Psychedelic Stud. 5 (2), 114\u2013127 (2021).","journal-title":"J. Psychedelic Stud."},{"key":"37609_CR23","doi-asserted-by":"publisher","unstructured":"Aday, J. et al. Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically [Preprint]. (2024). https:\/\/doi.org\/10.13140\/RG.2.2.29745.80489","DOI":"10.13140\/RG.2.2.29745.80489"},{"issue":"12","key":"37609_CR24","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","volume":"49","author":"P Peduzzi","year":"1996","unstructured":"Peduzzi, P., Concato, J., Kemper, E., Holford, T. R. & Feinstein, A. R. A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 49 (12), 1373\u20131379 (1996).","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"37609_CR25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1037\/1082-989X.1.1.16","volume":"1","author":"PJ Curran","year":"1996","unstructured":"Curran, P. J., West, S. G. & Finch, J. F. The robustness of test statistics to nonnormality and specification error in confirmatory factor analysis. Psychol. Methods. 1 (1), 16\u201329 (1996).","journal-title":"Psychol. Methods"},{"key":"37609_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12954-019-0308-4","volume":"16","author":"T Anderson","year":"2019","unstructured":"Anderson, T. et al. Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct. J. 16, 43 (2019).","journal-title":"Harm Reduct. J."},{"issue":"1","key":"37609_CR27","doi-asserted-by":"publisher","first-page":"22479","DOI":"10.1038\/s41598-021-01811-4","volume":"11","author":"JM Rootman","year":"2021","unstructured":"Rootman, J. M. et al. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Sci. Rep. 11 (1), 22479 (2021).","journal-title":"Sci. Rep."},{"issue":"12","key":"37609_CR28","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn, I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J. Psychopharmacol. 30 (12), 1259\u20131267 (2016).","journal-title":"J. Psychopharmacol."},{"key":"37609_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00897","author":"ECHM Haijen","year":"2018","unstructured":"Haijen, E. C. H. M. et al. Predicting responses to psychedelics: A prospective study. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2018.00897 (2018).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"37609_CR30","first-page":"1","volume":"6","author":"SL Russ","year":"2019","unstructured":"Russ, S. L., Carhart-Harris, R. L., Maruyama, G. & Elliott, M. S. States and Trais related to the quality and consequences of psychedelic experiences. Psychol. Conscious. (Wash DC). 6 (1), 1\u201321 (2019).","journal-title":"Psychol. Conscious. (Wash DC)"},{"issue":"7","key":"37609_CR31","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/0269881118754710","volume":"32","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris, R. L. et al. Psychedelics and the essential importance of context. J. Psychopharmacol. 32 (7), 725\u2013731 (2018).","journal-title":"J. Psychopharmacol."},{"key":"37609_CR32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s44220-025-00417-3","volume":"3","author":"DH Grossman","year":"2025","unstructured":"Grossman, D. H. et al. A systematic review of income and education reporting in psychedelic clinical trials. Nat. Mental Health. 3, 567\u2013574 (2025).","journal-title":"Nat. Mental Health"},{"issue":"2","key":"37609_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/02791072.1997.10400190","volume":"29","author":"B Eisner","year":"1997","unstructured":"Eisner, B. Set, setting, and matrix. J. Psychoact. Drugs. 29 (2), 213\u2013216 (1997).","journal-title":"J. Psychoact. Drugs"},{"issue":"7","key":"37609_CR34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamapsychiatry.2023.1554","volume":"80","author":"R Palitsky","year":"2023","unstructured":"Palitsky, R. et al. Importance of integrating spiritual, existential, religious, and theological components in psychedelic-assisted therapies. JAMA Psychiatry. 80 (7), 743 (2023).","journal-title":"JAMA Psychiatry"},{"key":"37609_CR35","doi-asserted-by":"publisher","first-page":"26372","DOI":"10.1007\/s12144-024-06272-2","volume":"43","author":"WA Schutt","year":"2024","unstructured":"Schutt, W. A., Exline, J. J., Pait, K. C. & Wilt, J. A. Psychedelic experiences and long-term spiritual growth: a systematic review. Curr. Psychol. 43, 26372\u201326394 (2024).","journal-title":"Curr. Psychol."},{"key":"37609_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/frcha.2024.1361617","author":"N Izmi","year":"2024","unstructured":"Izmi, N., Carhart-Harris, R. L. & Kettner, H. Psychological effects of psychedelics in adolescents. Front. Child. Adolesc. Psychiatry. https:\/\/doi.org\/10.3389\/frcha.2024.1361617 (2024).","journal-title":"Front. Child. Adolesc. Psychiatry."},{"issue":"6","key":"37609_CR37","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s44220-024-00252-y","volume":"2","author":"BD Hanshaw","year":"2024","unstructured":"Hanshaw, B. D., Fusunyan, M., Anderson, C. T. M. & Turban, J. L. Psychedelic-assisted therapy among sexual and gender minority communities. Nat. Ment Health. 2 (6), 636\u2013644 (2024).","journal-title":"Nat. Ment Health"},{"issue":"4","key":"37609_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1089\/psymed.2022.0018","volume":"1","author":"NA Carlisle","year":"2023","unstructured":"Carlisle, N. A., Dourron, H. M., MacCarthy, S., Zarrabi, A. J. & Hendricks, P. S. Exploring the unique therapeutic potential of psychedelics to reduce chronic shame among sexual and gender minority adults. Psychedelic Med. 1 (4), 210\u2013217 (2023).","journal-title":"Psychedelic Med."},{"key":"37609_CR39","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2024.0025","author":"R Katkar","year":"2025","unstructured":"Katkar, R., Perez, A. M., Altinay, M. & Barnett, B. S. Exploring gender-themed lysergic acid diethylamide experiences: A subreddit analysis. Psychedelic Med. https:\/\/doi.org\/10.1089\/psymed.2024.0025 (2025).","journal-title":"Psychedelic Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37609-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37609-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:08:39Z","timestamp":1771434519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37609-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37609"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37609-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.S.H. was previously in paid advisory relationships with Eleusis Benefit Corporation, Journey Colab Corporation, Reset Pharmaceuticals Inc., and Silo Pharma, and is currently in paid advisory relationships with Bright Minds Biosciences Ltd. and holds stock options in Beckley Psytech. P.S.H. is also co-founder of Equulus Therapeutics and Mycelial Health. O.S. was a co-founder of Eudelics AB. No financial conflicts of interest were reported by any other authors of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6458"}}